Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company's clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena's lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/08/13 | $23,000,000 | Series A |
Alta Partners Pappas Ventures RiverVest Venture Partners | undisclosed |
| 03/11/14 | $45,000,000 | Series B |
Adage Capital Partners Alta Partners Pappas Ventures RA Capital RiverVest Venture Partners | undisclosed |
